SMO and autosomal dominant polycystic kidney disease: Pharmacological inhibition of SMO reduces cystogenesis in other in vitro PKD models, including metanephric cystic explants and human primary ADPKD cells, as well as in vivo in the Pck rat model of ARPKD (Chan et al., 2010; Sato et al., 2018; Silva et al., 2018; Tran et al., 2014).